Serum neuropeptide Y was significantly elevated in first-episode schizophrenia patients compared to healthy controls, and correlated with symptom severity in males but not females.
p<0.001 sex interactionThe interaction between NPY levels and sex in predicting schizophrenia symptom severity was highly significant, with male patients showing strong NPY-symptom correlations absent in females
What the researchers found
Serum NPY levels were significantly higher in first-episode schizophrenia patients than controls (p<0.001). In males, NPY positively correlated with PANSS symptom scores at baseline (p<0.01) and changes in NPY tracked with symptom changes during risperidone treatment (p<0.05). No such correlations were found in females. The NPY × sex interaction was highly significant (p<0.001).
Why it matters
Understanding sex differences in schizophrenia has been a long-standing challenge. This study provides concrete biological evidence that neuropeptide Y — a molecule involved in stress response and brain signaling — behaves differently in male versus female schizophrenia patients. This could eventually lead to sex-specific treatment approaches.
The numbers in context
115 first-episode schizophrenia patients and 58 matched healthy controls. NPY measured at baseline and after 10 weeks of risperidone treatment.
How the study worked
Case-control cohort study with 115 first-episode schizophrenia patients and 58 matched healthy controls. Serum NPY measured at baseline and after 10 weeks of risperidone treatment in patients. Symptoms assessed with the Positive and Negative Syndrome Scale (PANSS). 95 patients completed the full study protocol.
Who was studied
First-episode schizophrenia patients and healthy controls
What this study cannot tell us
Moderate sample size with only 95 completing follow-up. All patients were treated with risperidone, so findings may not generalize to other antipsychotics. Serum NPY may not fully reflect brain NPY levels. The study didn't control for potential confounders like hormonal status in female patients. First-episode patients may differ from chronic schizophrenia populations.
How to read the evidence
Moderate evidence from a well-designed cohort study with appropriate controls and longitudinal measurement. Moderate sample size and single-site design limit generalizability.
When this study was published
Published in 2024, contributing to the growing understanding of neuropeptide biomarkers in psychiatric disorders.
The bigger picture
Schizophrenia affects men and women differently in onset, symptom profiles, and treatment response, but the biological reasons remain unclear. NPY's sex-specific role in symptom severity adds to growing evidence that schizophrenia may involve partially different biological pathways in males and females, which has implications for developing more targeted treatments.
Questions still open
- What hormonal or genetic factors drive the sex difference in NPY's relationship to schizophrenia symptoms?
- Would NPY-targeted therapies be more effective in male schizophrenia patients given the stronger symptom correlation?
Common questions
Why would NPY be elevated in schizophrenia?
Why would NPY affect male and female schizophrenia patients differently?
Read the original research
Neuropeptide Y in first-episode schizophrenia: is there any sex differences in the pathogeneses of schizophrenia?
Frontiers in psychiatry, 15, 1514475
Citation
Song, Jia-Qi; Xin, Wen; Yu, Jian-Jin; Zhao, Qing; Li, Hong-Na; Chen, Da-Chun. (2024). Neuropeptide Y in first-episode schizophrenia: is there any sex differences in the pathogeneses of schizophrenia?. Frontiers in psychiatry, 15, 1514475. https://doi.org/10.3389/fpsyt.2024.1514475